EU and US could reach trade deal this weekend - Reuters
On Tuesday, Cantor Fitzgerald reaffirmed its positive stance on Avita Medical Ltd . (NASDAQ:RCEL), maintaining an Overweight rating and a price target of $19.00. The endorsement comes despite the company’s shares experiencing a significant decline, approximately 36% from the year-to-date high of $14.06 on January 7, 2025. According to InvestingPro data, analyst consensus remains strongly bullish with a mean price target suggesting 70% upside potential, while the stock’s beta of 1.57 indicates higher volatility than the broader market. This downturn was primarily attributed to Avita Medical (TASE:BLWV)’s announcement of reduced revenue guidance for the fourth quarter of 2024, which was impacted by slower hospital purchasing activities and a challenging macroeconomic environment. Despite these challenges, InvestingPro analysis indicates the company maintains strong financial flexibility with a healthy current ratio of 2.83 and moderate debt levels. Get access to 8 more exclusive InvestingPro Tips and comprehensive financial analysis through the Pro Research Report.
Stifel analysts have expressed a belief that Avita Medical is positioned to outperform market expectations. They encourage investors to consider purchasing shares, suggesting that the current negative sentiment towards the company could present a buying opportunity. The analysts pointed to Avita Medical’s anticipation of deferred purchases from significant clients, which are expected to contribute to the company’s performance in the first quarter of 2025. This optimism comes despite the company’s current challenges, with InvestingPro data showing a revenue growth of 28.14% in the last twelve months, though profitability remains a concern.
Avita Medical is also looking forward to the release of new products, namely Mini and Cohealyx. Stifel’s analysts are confident that these launches will bolster the company’s ability to meet or surpass the revenue guidance set for the fiscal year 2025. This optimism is based on the potential of these products to resonate well with the market and drive sales growth. The company maintains an impressive gross profit margin of 85.85%, according to InvestingPro data, suggesting strong pricing power for its innovative products.
The company’s forward-looking statements regarding expected deferred client purchases and the introduction of new products are pivotal factors in Stifel’s analysis. These elements are seen as key drivers that could facilitate Avita Medical’s recovery from the recent downturn and help achieve the financial targets for the upcoming fiscal year.
In other recent news, Avita Medical reported a year-over-year increase of approximately 29% in commercial revenue, totaling $18.4 million, although this figure fell short of both Cantor Fitzgerald’s estimate of $23.9 million and the FactSet consensus of $23.0 million. Despite the revenue shortfall, Avita reiterated its fiscal year 2025 revenue forecast of $100 million to $106 million, suggesting a significant growth trajectory. Cantor Fitzgerald maintained an Overweight rating with a $19.00 price target, while Lake Street Capital Markets adjusted its price target from $20 to $14 but retained a Buy rating. Avita Medical recently received FDA approval for its RECELL GO Mini, a device aimed at treating smaller wounds, which is expected to enhance its market reach. The company’s ongoing product expansion includes the anticipated launch of Cohealyx in the second quarter of 2025, which is projected to significantly increase the addressable market for burn treatments. D. Boral (OTC:BOALY) Capital initiated coverage on Avita with a Buy rating and a $25.00 price target, citing strong growth prospects based on U.S. market penetration. Avita’s strategic focus on innovative skin regeneration products, such as RECELL, is anticipated to drive future growth and market adoption. The company’s efforts are being closely monitored by investors as it prepares to roll out new products, potentially solidifying its presence in the wound care market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.